Geoffrey von Maltzahn, Flagship General Partner and co-founder & CEO of Flagship-founded Tessera Therapeutics, explains Tessera's novel gene writing bioplatform and its vast potential for preventing and curing disease.
More from:
Human Health,
Sustainability
Pioneering Partnerships: Accelerating our Collaboration with Pfizer
Unlocking Therapeutic Breakthroughs with the Power of Platform Technologies
Halting the Trajectory of Disease with Preemptive Health
AI in Action
2025 CEO Chat: Torben Straight Nissen, CEO of Repertoire Immune Medicines
